


**Product Name** : MI-3454  
**Cat. No.** : PC-72046  
**CAS No.** : 2134169-43-8  
**Molecular Formula** : C<sub>32</sub>H<sub>35</sub>F<sub>3</sub>N<sub>8</sub>OS  
**Molecular Weight** : 636.742  
**Target** : Histone Methyltransferase (HMTase)  
**Solubility** : 10 mM in DMSO



## Biological Activity

MI-3454 (MI 3454) is a highly potent, orally bioavailable inhibitor of the **menin-MLL1** interaction with IC<sub>50</sub> of 0.51 nM, 60-fold improvement over MI-503.

MI-3454 inhibits growth of human MLL leukemic cell lines (MLL-tr): MV-4-11, MOLM-13, KOPN-8, SEM, RS4-11 with GI<sub>50</sub> values of 7-27 nM in MTT cell viability assays, does not significantly (>100-fold) affect the growth of leukemic cells without MLL1 translocations.

MI-3454 (50 nM or lower) led to downregulated expression of HOXA9 and MEIS1 in MV-4-11 and MOLM13 cells, also reduced other MLL fusion target genes, including MEF2C, DLX2, HOXA10, PBX3, and FLT3.

MI-3454 demonstrated strong reduction of cell proliferation and downregulation of HOXA9 and MEIS1 expression in mouse bone marrow cells transformed with the MLL-AF9 oncogene but not in bone marrow cells transformed with HOXA9 and MEIS1 oncogenes.

MI-3454 induces leukemia regression in xenograft model of MLL leukemia through on-target activity.

MI-3454 (3–12 nM) substantially reduced clonogenic potential in MLL leukemia patient samples with MLL1 translocations or NPM1 mutations, MI-3454 induced complete remission or blocks leukemia progression in PDX models of MLL leukemia.

## References

Klossowski S, et al. *J Clin Invest*. 2020 Feb 3;130(2):981-997.

Miao H, et al. *Blood*. 2020 Dec 17;136(25):2958-2963.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com